AbbVie Inc. · 2026-11-03 · Importance 37 · Surprise 6
AbbVie reported 2026 net revenues of $17.4 billion, significantly higher than the prior year. Net income was $4.22 billion, and diluted EPS was $2.37. Growth was driven by Skyrizi and Rinvoq, which offset Humira's decline; the report also cited new FDA approvals and significant R&D investments.
Key facts
AbbVie reported 2026 net revenues of $17.4 billion, net income of $4.22 billion, and diluted EPS of $2.37. source
AbbVie’s growth was driven by Skyrizi and Rinvoq, offsetting Humira’s decline. source